A detailed history of Founders Financial Securities LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Founders Financial Securities LLC holds 1,113 shares of VRTX stock, worth $502,218. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,113
Previous 1,259 11.6%
Holding current value
$502,218
Previous $590,000 12.37%
% of portfolio
0.05%
Previous 0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$460.0 - $505.78 $67,160 - $73,843
-146 Reduced 11.6%
1,113 $517,000
Q2 2024

Aug 02, 2024

BUY
$392.81 - $485.53 $28,675 - $35,443
73 Added 6.16%
1,259 $590,000
Q1 2024

Apr 17, 2024

BUY
$407.69 - $446.08 $75,014 - $82,078
184 Added 18.36%
1,186 $495,000
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $9,604 - $11,499
28 Added 2.87%
1,002 $407,000
Q3 2023

Oct 17, 2023

BUY
$338.18 - $362.46 $24,687 - $26,459
73 Added 8.1%
974 $338,000
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $52,508 - $58,768
167 Added 22.75%
901 $317,000
Q4 2022

Feb 08, 2023

SELL
$285.76 - $321.48 $19,431 - $21,860
-68 Reduced 8.48%
734 $211,000
Q3 2022

Oct 27, 2022

SELL
$273.83 - $305.53 $15,608 - $17,415
-57 Reduced 6.64%
802 $232,000
Q2 2022

Jul 27, 2022

SELL
$234.96 - $292.55 $71,427 - $88,935
-304 Reduced 26.14%
859 $242,000
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $24,799 - $29,228
112 Added 10.66%
1,163 $304,000
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $186,037 - $234,845
1,051 New
1,051 $231,000
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $180,845 - $202,381
-997 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $186,927 - $220,436
997 New
997 $201,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Founders Financial Securities LLC Portfolio

Follow Founders Financial Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Founders Financial Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Founders Financial Securities LLC with notifications on news.